CN-121991171-A - Red bean polypeptide for preventing and treating ulcerative colitis and application thereof

CN121991171ACN 121991171 ACN121991171 ACN 121991171ACN-121991171-A

Abstract

The application belongs to the technical field of bioactive peptides, and provides a small red bean polypeptide for preventing and treating ulcerative colitis and application thereof, wherein the amino acid sequence of the small red bean polypeptide is IFNNDPNNHP. The small red bean polypeptide can obviously reduce DAI score of a DSS colitis mouse, relieve the shortening of colon length of the DSS colitis mouse, improve the erosion and ulcer degree of colon mucosa, has better prevention and treatment effects on ulcerative colitis, has a simple preparation method, is easy for industrial production, and has certain drug research and development and clinical application values.

Inventors

ZHAO QINGYU
ZHOU HANG
SHEN QUN
HAO ZHIHUI
MA ZHIHAO
WANG SHIMING
WU LIYANG

Assignees

中国农业大学

Dates

Publication Date: 20260508
Application Date: 20260311

Claims (10)

1. A small red bean polypeptide for preventing and treating ulcerative colitis, characterized in that the amino acid sequence of the small red bean polypeptide is IFNNDPNNHP.
2. Use of a small red bean polypeptide according to claim 1 in the manufacture of a medicament for the prevention or treatment of ulcerative colitis.
3. The use according to claim 2, wherein the medicament further comprises a pharmaceutically acceptable carrier.
4. The use according to claim 2 or 3, wherein the medicament is in an oral dosage form.
5. The use of claim 2, wherein the medicament reduces DAI scores for treatment of ulcerative colitis, improves symptoms of colonic shortening and/or improves colonic mucosal erosion and ulceration.
6. A pharmaceutical composition for treating ulcerative colitis, comprising a small red bean polypeptide according to claim 1 and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition of claim 6, wherein the drug is in an oral dosage form.
8. The method for producing a small red bean polypeptide according to claim 1, which is a method for synthesizing the small red bean polypeptide in a solid phase.
9. The method of manufacturing according to claim 8, characterized in that the method of manufacturing comprises: (1) Soaking N, N-dimethylformamide and methanol by using a molecular sieve to remove impurities; (2) Swelling N, N-dimethylformamide to activate Wang resin; (3) Connecting a first amino acid; (4) Fmoc protecting group removal; (5) Grafting a second amino acid and removing Fmoc protecting groups; (6) Repeating the step (5) until the last Fmoc protecting group is synthesized and removed; (7) The resin is removed and detected by analytical high performance liquid chromatography and mass spectrometry.
10. The method for producing a small red bean polypeptide according to claim 1, wherein the method for producing a small red bean polypeptide is a method for expressing the small red bean polypeptide using a genetically engineered bacterium.

Description

Red bean polypeptide for preventing and treating ulcerative colitis and application thereof Technical Field The invention belongs to the technical field of bioactive peptides, and particularly relates to a small red bean polypeptide for preventing and treating ulcerative colitis and application thereof. Background Ulcerative Colitis (UC) is a chronic inflammatory disease of the colon that severely affects physical and mental health and social development. Previous studies have considered that developing countries have a somewhat lower prevalence, but with the progress of urbanization, the incidence of UC in developing countries may increase year by year as the diet and living environment change. The etiology and pathogenesis of UC are not completely defined, but are multifactorial, including genetic susceptibility, epithelial barrier deficiency, immune response imbalance, etc. Although the exact cause of UC is not known, it is thought to be due to disruption of the balance between the intestinal microbiota and the mucosal immune system. This imbalance is driven by both genetic and environmental factors. The UC treatment mode mainly adopts drug treatment, and comprises an aminosalicylic acid preparation, hormone, immunosuppressant, biological preparation and small molecule drug. The treatment aims at inhibiting inflammatory reaction, maintaining symptom relief, and the long-term aims at preventing colorectal cancer, avoiding colectomy, limiting long-term use of steroid drugs, promoting mucous membrane healing and improving life quality of patients. Corticosteroids are not suitable for long-term use due to their side effects and tolerance. The aminosalicylic acid preparation is used for induction relief and maintenance treatment of light and moderate UC, but has large difference in curative effect and easy recurrence in maintenance period, the hormone is only used for induction relief of moderate and severe patients, the dry maintenance treatment cannot be used, and many patients have hormone resistance or hormone dependence, and in addition, the biological preparation has high price and is limited to be widely applied. The research and development of safe and effective medicines for preventing and treating ulcerative colitis has become a research and development hot spot in the related fields at home and abroad. The red bean is mature seed of red bean of leguminous plant, is a high protein, low fat and high carbohydrate food, has important functions of resisting oxidation, reducing blood sugar, resisting inflammation, enhancing immunity and the like, and is a bean variety with excellent medicine and food. Red bean has the efficacy of "eliminating heat toxin (modern medicine is mostly regarded as an inflammatory state)", recorded in Shennong Ben Cao Jing ". Epidemiological studies have shown that legume food intake has potential benefits in reducing the risk of chronic disease, but the specific ingredients or bioactive substances in legumes have not been identified. In recent years, more research has focused on bioactive peptides after proteolysis, considering the postnatal processes of digestion and absorption of foods in the human body. The small red bean polypeptide is a substance prepared by the enzymolysis of small red bean protein, a specific small peptide separation technology and the like, has various biological activity functions such as anti-inflammatory function and the like, and is an excellent source for excavating novel biological activity peptides. Disclosure of Invention Early researches found that red bean and protein hydrolysate thereof can effectively relieve inflammation and intestinal mucosa barrier injury induced by high-fat diet, and further researches found that red bean IFNNDPNNHP (IP-10) peptide is a key active substance in red bean and has prevention and treatment effects on ulcerative colitis. In one aspect, the application provides a small red bean polypeptide for preventing and treating ulcerative colitis, wherein the small red bean polypeptide has an amino acid sequence IFNNDPNNHP. In another aspect, the application provides application of the small red bean polypeptide in preparing a medicament for preventing or treating ulcerative colitis. Further, the medicine also comprises a pharmaceutically acceptable carrier. Further, the medicament is in an oral dosage form. Further, the medicament reduces DAI scores for treatment of ulcerative colitis, improves symptoms of colonic shortening and/or improves colonic mucosal erosion and ulceration. In another aspect, the application provides a pharmaceutical composition for treating ulcerative colitis, comprising a small red bean polypeptide as described above and a pharmaceutically acceptable carrier. Further, the medicament is in an oral dosage form. In another aspect, the application provides a method for preparing the small red bean polypeptide, which is a method for synthesizing the small red bean polypeptide in a solid phase. Furthe